Lawrence Florin

BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC.

BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC.

BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC.

BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC.

BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC.